Overview

Shift the focus to improving patient experience, care, and practice success 

Empower your practice to focus on patient care with streamlined administrative solutions

Get in touch with our team for provider client support

Demo CTA

Overview

Ensure patients can start and stay on the therapies they need by removing obstacles at every step of their journey

Our focus has been deeply rooted in one common theme from the beginning — that patients are the priority

Keep up to date on news and announcements at CareMetx

Join our team

Meet with us

A Conversation with Mark Hansan, CareMetx

CareMetx was founded in 2011 by two longtime industry executives, Bob Dresing and Mark Hansan, who started in the patient support field in the 1980s. Dresing is now chairman; Hansan is CEO. In 2018, it acquired VirMedica, a leading e-services company in the Hub industry, and BioSolutia, an award-winning Hub company in Lake Mary, FL. Today it has five offices and operates as a national patient access company offering turn-key solutions, proprietary e-services and collaborative patient support programs. Most recently, it launched a new business unit, OutcomeRx, designed to provide holistic solutions for new personalized medicines, such as cellular and genetic therapies, that require innovative value-based contracting between manufacturers and payers.

Pharmaceutical Commerce sat down with Hansan; here’s what he had to say about the evolving hub services/patient support arena.

 

Patient Support / Hub Services Continue to Evolve

The goal of producing meaningful data is driving industry progress. The business of providing outsourced patient support and hub services is growing...

Read More

Here’s Why You Should Retain Allscripts (MDRX) Stock For Now

Allscripts Healthcare Solutions, Inc. MDRX is well-poised for growth in the coming quarters, backed by its strategic alliances over the past few...

Read More

Value-based agreements could disrupt how we pay for new therapies

On Tuesday, the Senate Finance Committee will hold its second hearing in a series on drug pricing. Led by chairman Senator Chuck Grassley (R-Iowa)...

Read More